• In February 2026, Arrowhead Pharmaceuticals received US FDA approval for its first drug, REDEMPLO (plozasiran), for familial chylomicronemia syndrome, with additional regulatory clearances in China and Canada and an early US launch supported by over 100 initial prescriptions and a dedicated patient support program.
• This approval shifts Arrowhead from a purely R&D-focused biotech to a commercial-stage company, potentially reshaping how investors view its revenue mix, risk profile, and dependence on partnership income.
• Now we’ll explore how becoming a commercial-stage company with REDEMPLO approved could reshape Arrowhead’s previously partnership-heavy investment narrative.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Arrowhead Pharmaceuticals Investment Narrative Recap

To own Arrowhead today, you need to believe that REDEMPLO’s first commercial approval can eventually support a sustainable, less partnership‑dependent business, while the company manages costs and execution risk around its broader RNAi pipeline. The REDEMPLO launch reduces Arrowhead’s previous all‑or‑nothing regulatory risk on plozasiran, but the key near term catalyst now shifts to how quickly prescriptions convert into recurring revenue, and whether that is enough to offset still‑rising operating expenses.

The most relevant recent update alongside REDEMPLO’s approval is Arrowhead’s strong Q1 FY2026 result, with sales of US$264.03 million and net income of US$30.81 million. While this performance was heavily influenced by collaboration revenue, it shows how partnered income and early product sales can together support profitability in the short term, even as the company invests in new programs such as ARO‑DIMER‑PA and continues to build out its commercial infrastructure.

Yet even as REDEMPLO comes to market, investors should be aware that...

Arrowhead Pharmaceuticals' narrative projects $398.8 million revenue and $64.0 million earnings by 2028. This implies an 11.4% yearly revenue decline but an earnings increase of about $212.4 million from -$148.4 million today.

Uncover how Arrowhead Pharmaceuticals' forecasts yield a $64.08 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts saw revenue falling about 48.6 percent a year to just US$77.9 million by 2028, highlighting much deeper concern about pricing pressure and RNAi competition than the consensus view, and reminding you that opinions on Arrowhead’s post REDEMPLO future can diverge sharply.

Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.